Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

May 15, 2012 (Vol. 32, No. 10)

Reducing Uncertainty Surrounding Biosimilar Production

  • On paper, biosimilars have great potential to cut development costs, expand patient access to biologics, and improve affordability. The practical reality is that these goals are difficult to achieve. Technology isn’t the biggest problem, say experts. Intellectual property challenges, added costs to characterize reference products, and uncertainty around ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.